Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Mar 18, 2022

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

Mar 17, 2022

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

Mar 9, 2022

Journey Medical Corporation to Present at the 34th Annual ROTH Conference

Feb 11, 2022

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

Jan 13, 2022

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.

Dec 10, 2021

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

Dec 7, 2021

Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference

Nov 29, 2021

Journey Medical Corporation Introduces Expanded Board of Directors

Nov 16, 2021

Journey Medical Corporation Announces Closing of Initial Public Offering

Nov 12, 2021

Journey Medical Corporation Prices $35.2 Million Initial Public Offering

rss_feed News RSS